The Centre for Biosimilars reports new study on FDA biosimilar naming requirements

The Centre for Biosimilars reports a new study published in Diabetes Spectrum suggests FDA biosimilar naming requirements and switching restrictions cause patients to perceive biosimilars as less similar to reference products. The authors linked the requirement for a biosimilar product to use a four letter suffix and restrictions on pharmacy interchangeability to a diminished interest in biosimilars among patients.